



**Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208
Particular Matter Waiver**

SGE: Clyde W. Yancy, M.D.

Committee: Circulatory System Devices Panel of FDA’s Medical Devices Advisory
Committee

Meeting Date(s): November 29, 2007

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: a premarket approval application (PMA) submitted by Abbott Vascular (a subsidiary of Abbott Laboratories) for the *XIENCE™ V Everolimus Eluting Coronary Stent System* which is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 28 mm) with reference vessel diameter of 2.5mm to 4.0mm, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	Involvement	Magnitude
Consulting	on an unrelated product in a competing firm	less than \$10,001
Consulting	on an unrelated product in an unaffected unit of the parent of competing firms	less than \$10,001

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waiver is not valid.

/S/
Signature

10/23/07
Date